Hope for everyone dealing with cancer.
At Elekta, we have a united PURPOSE that motivates us as a company and as individuals—Hope for everyone dealing with cancer. It drives us towards our VISION – A world where everyone has access to the best cancer care. And we plan to get there through our MISSION – We improve patient lives by working together with our customers and partners.
As a leading innovator of precision radiation therapy solutions, Elekta is committed to ensuring that every patient has access to the best cancer care possible.
Our offering allows clinicians to treat more patients with increased quality, both with value-creating innovations in solutions and AI-supported service based on a global network.
Towards a world where everyone has access to the best cancer care
For almost half a century we've been working openly and proactively with clinicians and our partners to develop outcome-driven and cost-efficient solutions that meet evolving patient needs, no matter where they are in the world. To us it's personal and our global team of 4,700 employees combine passion, science and imagination to profoundly change cancer care, improve patient care and bring hope to everyone dealing with cancer.
“Today's shortage in radiotherapy equipment is unacceptable. We have a responsibility to change this and will do our part by delivering new, innovative solutions for cancer care."
Gustaf Salford, President and CEO
![Infographic: '28 million - projected increase of new cancer cases per year by 2040 (1). Cancer is growing twice as fast as other diseases and is likely to become the leading cause of death globally in a few decades. Currently there is a shortage of [more than] 15,000 linacs globally (2), we need to close this gap. 50-60% of all cancer patients will need radiation therapy, but lack access to treatment. Low- and middle- income countries have 80% of the global cancer burden but have access to only 32% of global radiation therapy resources (3)'](about_us_infographic.svg)
Our strategy to improve cancer care
We want to do our part to move towards a world where everyone has access to the best cancer care. With our strategy ACCESS 2025 we set the focus on closing the access gap, elevating cancer care and increasing the patients' participation in their own care.
What does access to the best cancer care mean to Elekta?
AVAILABILITY of Care
Improving physical access to radiation therapy globally. By growing the installed base (the numbers of machines) in underserved markets, we want to ensure that a larger share of the global population has access to radiation therapy.
2025 MILESTONE
+300M people
to gain access to RT via 825
additional Elekta linacs in underserved markets
ELEVATION of Care
Improving patient access to better and more efficient care by driving clinical adoption of new technology, optimal utilization of available technology and improving clinical decision support.
2025 MILESTONE
2x to 4x
double the clinical usage of short
course treatment (hypofractionation) and quadruple the usage of adaptive
treatments among Elekta customers
PARTICIPATION in Care
Increasing patient involvement in their own care journey and enhancing the care teams' ability to improve clinical outcomes through access to deeper and richer patient-reported insights.
2025 MILESTONE
+20%
of Elekta customers’ patients are actively
interacting with their own care journey (<1% today)
Experience the difference
Discover how partnering with Elekta gives you access to versatile solutions, a culture of innovation and a true commitment to partnership.
Learn more
- WHO Report on cancer, available at https://www.who.int/publications/i/item/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all (excl. non-melanoma skin cancer).
- Ferlay J, et al. Global Cancer Observatory: Cancer Tomorrow. Lyon: International Agency for Research on Cancer, 2020; UN World Population Prospects 2019; International Atomic Energy Agency: DIRAC (Directory of Radiotherapy Centres), 2021
- Atun et al, Expanding global access to radiotherapy, The Lancet Oncol 2015 Sep; 16(10): 1153-86 https://pubmed.ncbi.nlm.nih.gov/26419354/ .